The specialty drug pipeline for 2018 is poised to deliver huge growth and clinical breakthroughs for a relatively narrow but challenging group of patients, with plenty of competition on the horizon, according to Aimee Tharaldson, PharmD, a senior clinical consultant in emerging therapeutics at Express Scripts.
That outlook for 2018 underscores a more long-term market trend: By 2020, about half of the money spent on the pharmacy benefit will be on specialty drugs, yet these medications will be